New hope for stroke patients with cancer: antioxidant drug trial launches
NCT ID NCT07091994
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a drug called edaravone dexborneol can help people who have a stroke while also having active cancer. The drug is given by IV twice a day for 10-14 days. Researchers will check if it improves recovery and is safe. About 144 adults aged 18-80 will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- edaravone dexborneol injection (a combination antioxidant and anti-inflammatory drug)
- What this could lead to
- If it works, this could offer a new treatment option for stroke patients with active cancer, who currently have limited choices.
- What could go wrong
- This is a Phase 4 trial with only 144 participants, so results may not apply to everyone. The drug may not improve outcomes or could cause side effects in this high-risk group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanfang Hospital, Southern Medical University
Guangzhou, Baiyun, 510515, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an earthworm enzyme boost stroke recovery?
- Can a Rapid-Acting clot blocker boost stroke recovery?
- Can a common antibiotic shield the brain after a stroke?
- Can a simple relaxation technique soothe the mind after a stroke?
- Stroke care at a distance: can video consultations speed up Life-Saving treatment?
- Herbal capsule may boost brain repair after stroke